Table 3. Number of CRC and extra-colonic tumors according to clinical criteria and mutation status.
| Amsterdam I & II | Bethesda | Odds Ratio (95%CI- carriers) | |||
|---|---|---|---|---|---|
| MMR Carriers | MMR noncarriers | MMR carriers | MMR noncarriers | ||
| Families (N = 116) | 31 | 18 | 15 | 52 | |
| Individuals (N = 2365) | 911 (421 F/490 M) | 477 (216 F/261 M) | 103 (56 F/47 M) | 874 (443 F/431 M) | |
| Colorectal cancer (N = 325) | 159 | 62 | 21 | 88 | 1.6 (1.3–1.9) |
| Extra-colonic tumors (N = 163) | |||||
| Endometrial | 16 | 0 | 2 | 1 | 25.8 (3.4–198) |
| Pelvis renal | 9 | 1 | 0 | 0 | 12 (1.5–94) |
| Small-bowel | 1 | 0 | 0 | 2 | 0.66 (0.06–7.3) |
| Uterine | 6 | 4 | 1 | 2 | 1.6 (0.5–4.8) |
| Gastric | 11 | 6 | 5 | 17 | 0.92 (0.5–1.7) |
| Hepatobiliar | 2 | 0 | 1 | 1 | 4 (0.4–38) |
| Ovarian | 2 | 0 | 0 | 2 | 1.38 (0.2–9.8) |
| Pancreas | 4 | 1 | 0 | 7 | 0.66 (0.2–2.2) |
| CNS | 4 | 3 | 0 | 3 | 0.88 (0.2–3.1) |
| Sebaceous | 2 | 0 | 2 | 0 | 1.33 (0.18–9.4) |
| Breast | 4 | 10 | 3 | 19 | 0.32 (0.1–0.7) |
M:Male; F: Female